Size | Price | |
---|---|---|
5mg | ||
50mg | ||
500mg |
ln Vivo |
Plasma GH values are dramatically decreased by injecting 10 μg of alpha-helical corticotropin-releasing factor (9–41) once into the lateral ventricle or third ventricle [1]. The effect of alpha-helical corticotropin-releasing factor (9-41) (100 ng/kg; icv once) on the increase of splenic sympathetic nerve activity generated by rhlL-11/β is discussed [2].
|
---|---|
Animal Protocol |
Animal/Disease Models: Adult SD (SD (Sprague-Dawley)) rat [1]
Doses: 10 μg Route of Administration: Injection into the third ventricle or lateral ventricle of the brain; 10 μg once Experimental Results:Elimination of 10-minute electric shock - injected into the brain 45 minutes before stress The level of plasma GH produced by the third or lateral ventricle is diminished. Animal/Disease Models: Adult SD (SD (Sprague-Dawley)) rats [1] immunized with endogenous somatostatin (SS) Doses: 10 μg Route of Administration: intracerebroventricular injection; 10 μg One time Experimental Results:immunized to endogenous SS Neutralization has no effect on plasma GH values in rats but interferes with the stimulatory effects of GH releasing factor (GRF). Animal/Disease Models: Male Wistar rats were injected with rhlL-1/β[2]. Doses: 100 ng/kg. Route of Administration: intracerebroventricular injection; 100 ng/kg. Primary Experimental Results:complete blockade of splenic sympathetic nerves induced by rhlL-1/β. The activity was enhanced but failed to change the enhanced nociceptive behavior caus |
References |
[1]. Rivier C, Vale W. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. Endocrinology. 1985 Dec;117(6):2478-82.
[2]. Takakazu Oka, et al. Intracerebroventricular injection of interleukin-1/β induces hyperalgesia in rats. Brain Research, 624 (1993) 61-68. |
Molecular Formula |
C22H25IN2O6
|
---|---|
Molecular Weight |
540.348178625107
|
CAS # |
99658-03-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
IC1C=CC=CC=1C[C@@H](C(=O)OC)NC(C[C@H](CNC(=O)OCC1C=CC=CC=1)O)=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8507 mL | 9.2533 mL | 18.5065 mL | |
5 mM | 0.3701 mL | 1.8507 mL | 3.7013 mL | |
10 mM | 0.1851 mL | 0.9253 mL | 1.8507 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.